Combination chemotherapy with VM-26, adriamycin, bleomycin, and prednisone as a secondary treatment of malignant lymphoma

A. Goldhirsch, M. Pirovino, R. W. Sonntag, L. Tschopp, H. J. Ryssel, K. W. Brunner

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty-eight pretreated patients with Hodgkin's disease (HD) and malignant non-Hodgkin's lymphoma were given combination chemotherapy with VM-26, Adriamycin, bleomycin, and prednisone. Four of 15 evaluable patients with HD achieved a partial remission (PR), with a median duration of 8 months. Of 12 patients with diffuse poorly differentiated lymphocytic lymphoma, one achieved a complete remission (30+ months) and five achieved a PR (median, 6 months). One of three patients with histiocytic lymphoma had a PR of 1.5 months. There was one drug-related death. Five patients developed life-threatening hematologic toxicity. Two HD responders died of acute nonlymphocytic leukemia.

Original languageEnglish
Pages (from-to)335-337
Number of pages3
JournalCancer Treatment Reports
Volume64
Issue number2-3
Publication statusPublished - 1980

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Combination chemotherapy with VM-26, adriamycin, bleomycin, and prednisone as a secondary treatment of malignant lymphoma'. Together they form a unique fingerprint.

Cite this